What is HC Wainwright’s Forecast for Neurogene Q1 Earnings?

Neurogene Inc. (NASDAQ:NGNE) – Research analysts at HC Wainwright boosted their Q1 2026 EPS estimates for shares of Neurogene in a research report issued on Thursday, March 26th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($1.00) per share for the quarter, up from their previous forecast of ($1.04). HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. HC Wainwright also issued estimates for Neurogene’s Q2 2026 earnings at ($1.02) EPS, Q3 2026 earnings at ($1.05) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.16) EPS.

NGNE has been the topic of several other research reports. Canaccord Genuity Group started coverage on Neurogene in a research report on Friday, February 27th. They set a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, January 22nd. Lifesci Capital initiated coverage on Neurogene in a research note on Monday, January 26th. They set an “outperform” rating and a $50.00 price objective for the company. Finally, Wall Street Zen downgraded Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $44.00.

Neurogene Stock Up 4.5%

Shares of NGNE stock opened at $20.16 on Monday. The firm has a market cap of $313.89 million, a price-to-earnings ratio of -4.75 and a beta of 1.53. Neurogene has a 52-week low of $6.88 and a 52-week high of $37.27. The company’s 50 day moving average is $19.60 and its 200 day moving average is $21.70.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($1.12) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.08.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NGNE. Balyasny Asset Management L.P. acquired a new stake in Neurogene in the third quarter worth about $12,114,000. ArrowMark Colorado Holdings LLC increased its holdings in shares of Neurogene by 1.8% during the third quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock valued at $10,326,000 after acquiring an additional 10,442 shares in the last quarter. Jennison Associates LLC raised its position in shares of Neurogene by 35.3% in the 4th quarter. Jennison Associates LLC now owns 533,088 shares of the company’s stock valued at $10,982,000 after purchasing an additional 138,999 shares during the last quarter. State Street Corp raised its position in shares of Neurogene by 47.8% in the 4th quarter. State Street Corp now owns 307,797 shares of the company’s stock valued at $6,341,000 after purchasing an additional 99,487 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in Neurogene by 1.3% in the 4th quarter. Geode Capital Management LLC now owns 249,695 shares of the company’s stock worth $5,145,000 after purchasing an additional 3,262 shares in the last quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Stuart Cobb sold 6,797 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $141,445.57. Following the transaction, the insider directly owned 30,497 shares of the company’s stock, valued at approximately $634,642.57. This represents a 18.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Christine Mikail Cvijic sold 4,045 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $20.81, for a total value of $84,176.45. Following the sale, the chief financial officer owned 105,798 shares of the company’s stock, valued at approximately $2,201,656.38. This represents a 3.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 9.92% of the company’s stock.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.